Loading...

Intellectia LogoIntellectia
Auto Trade
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. 02162
02162 logo

02162 Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
52.650
Open
47.940
VWAP
51.30
Vol
2.41M
Mkt Cap
--
Low
47.640
Amount
123.51M
EV/EBITDA(TTM)
--
Total Shares
--
EV
1.57B
EV/OCF(TTM)
--
P/S(TTM)
13.28

Events Timeline

No data

No data

News

aastocks
8.5
01-19aastocks
Duoning Biotech Seeks Hong Kong Listing; WUXI BIO is Its Largest Client
  • Company Listing: Shanghai Duoning Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors.

  • Clientele and Services: The company provides bioprocess solutions and laboratory products to pharmaceutical companies, CROs, CDMOs, and research institutions, with major clients including top biopharmaceutical firms in China.

  • Key Clients: WuXi Biologics is highlighted as one of the largest clients and suppliers, along with other notable shareholders such as CSPC Pharma, Akeso, and Keymed Bio-B.

  • Market Activity: The article notes short selling activity and stock performance for several companies in the sector, indicating market dynamics and investor interest.

aastocks
6.5
2025-12-11aastocks
<Research>CMSI Forecasts Modest Economic Growth in the US Next Year; Hong Kong Stock Market to Transition Towards Earnings-Driven Performance
  • US Economic Outlook: The US economy is projected to experience moderate growth next year, supported by the Fed's rate cuts and AI investments, while maintaining a bullish stance on US stocks despite short-term risks.

  • Hong Kong Stock Market Forecast: Hong Kong stocks are expected to transition from valuation recovery to earnings growth, with liquidity remaining favorable despite challenges in China's economy.

  • Top Stock Recommendations: CMSI's top stock picks for Q1 2026 include major companies like Alphabet, Meta, Netflix, Tencent, and Alibaba, among others.

  • Short Selling Data: The report includes detailed short selling data for various stocks, highlighting significant short selling ratios for companies like Geely Auto and BYD Company.

aastocks
2.0
2025-10-08aastocks
M Stanley Unveils New Asian Thematic Focus List (Table)
  • Stock Performance Overview: Various companies in the tech and energy sectors are experiencing fluctuations in stock prices, with notable short selling activity reported for several firms, including Li Auto and Hesai Group.

  • Short Selling Ratios: Significant short selling ratios are observed across multiple companies, with Li Auto showing a high ratio of 38.992%, indicating investor skepticism about its future performance.

  • Market Trends in Longevity Sector: Companies like Innovent Bio and Heng Rui Pharma are seeing positive stock movements, while others like DualityBio-B are facing declines, reflecting mixed investor sentiment in the longevity sector.

  • Governance and Investment Insights: Major firms in Singapore, such as Singapore Exchange and CapitaLand Investment, are highlighted, with short selling data indicating varying levels of investor confidence in these companies.

aastocks
4.0
2025-09-22aastocks
<M Stanley Analysis: Ratings and Target Prices for Biotech Companies (Table)>
  • Stock Performance Overview: Various stocks such as VISEN PHARMA-B and AKESO show mixed performance, with VISEN PHARMA-B down by 1.138% and AKESO up by 1.002%.

  • Short Selling Activity: Significant short selling activity is noted across several stocks, including Zai Lab and INNOVENT BIO, with short selling ratios reaching as high as 30.955% for Zai Lab.

  • Analyst Ratings: Most stocks listed, including INNOVENT BIO and KEYMED BIO-B, are rated as "Outperform," indicating positive expectations from analysts.

  • Market Trends: The report highlights the top 10 HK stocks with the highest net buys and sells by Southbound funds, reflecting current market trends and investor interests.

aastocks
4.5
2025-08-05aastocks
<Full-day Takeaway>HSI Closes at 24,902, Up 169 pts; HSTI Closes at 5,521, Up 39 pts; BYD ELECTRONIC Up over 7%; XD INC, LEPU BIO, KEYMED BIO-B, AKESO, SKB BIO-B Hit New Highs; Market Turnover Rises
  • Market Performance: The Hang Seng Index (HSI) increased by 169 points (0.7%) to close at 24,902, with a market turnover of $229.40 billion. Major stocks like Tencent and CCB saw gains, while others like Xiaomi and Alibaba experienced slight declines.

  • Notable Stock Movements: BYD Electronic and Lenovo Group had significant increases of 7.7% and 5.1%, respectively, while XD Inc and Lepu Bio achieved remarkable gains of 24.8% and 14.8%, hitting new highs.

Wall Street analysts forecast 02162 stock price to rise
0 Analyst Rating
Wall Street analysts forecast 02162 stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for (02162.HK) is -24.45, compared to its 5-year average forward P/E of -21.51. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-21.51
Current PE
-24.45
Overvalued PE
-9.53
Undervalued PE
-33.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.90
Current EV/EBITDA
-26.56
Overvalued EV/EBITDA
-8.60
Undervalued EV/EBITDA
-33.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
56.52
Current PS
16.36
Overvalued PS
112.81
Undervalued PS
0.23

Financials

AI Analysis
Annual
Quarterly

Whales Holding 02162

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (02162) stock price today?

The current price of 02162 is 52.4 USD — it has increased 9.17

What is (02162)'s business?

What is the price predicton of 02162 Stock?

Wall Street analysts forecast 02162 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02162 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (02162)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (02162)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (02162). have?

(02162) has 0 emplpoyees as of March 06 2026.

What is (02162) market cap?

Today 02162 has the market capitalization of 0.00 USD.